GlassScriptPhysician profile
Keith A Georger
NPI 1649581745
$14,825.91
in general payments reported to CMS, 2019-2025
56 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $1,306 · 2021: $2,386 · 2022: $2,364 · 2023: $2,488 · 2024: $2,463 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,236 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,235.89 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,015.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,280.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,148.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,011.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $701.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $681.64 | 2019-2025 | |
| Allergan, INC. | $563.24 | 2019-2020 | |
| Amgen INC. | $442.14 | 2019-2025 | Repatha, Evenity, Otezla |
| Abbott Laboratories | $331.88 | 2020-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.73 | 2019-2024 | Jardiance, Spiriva Respimat |
| Amarin Pharma, INC. | $309.07 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.30 | 2019-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $307.46 | 2020-2025 | Rexulti |
| Axsome Therapeutics, INC. | $284.70 | 2022-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $235.85 | 2019-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Georger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.